Can targeting of IL-6 lead to CV protection in CKD? - PACE-CME

Can targeting of IL lead to CV protection in CKD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Renal denervation as option for patients with hypertension despite medications
Renal denervation as option for patients with hypertension despite medications
ACC.21
Renal denervation as option for patients with hypertension despite medications
- Prof. Ajay Kirtane, MD
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
ACC.21
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
- Prof. Derek Chew
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
ACC.21
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
- Prof. Freek Verheugt, MD
No definite difference for primary endpoint but proven safety with ARNI in MI patients
No definite difference for primary endpoint but proven safety with ARNI in MI patients
ACC.21
No definite difference for primary endpoint but proven safety with ARNI in MI patients
- Prof. Marc Pfeffer, MD, PhD